A study on the impact of SGLT2 inhibitors on survival in patients with non-small cell lung cancer (NSCLC) revealed that the use of these inhibitors was linked to prolonged overall survival in NSCLC patients who had diabetes prior to diagnosis, irrespective of demographic factors, tumor features, and treatment modalities 50. The gene discussed is SLC5A2; the disease is diabetes mellitus.